Krystal Biotech Announces Departure of Chief Commercial Officer
October 16 2020 - 4:10PM
Business Wire
Krystal Biotech, Inc. (Nasdaq:KRYS) today announced that Chief
Commercial Officer Jennifer Chien is leaving the company, effective
today, to pursue another opportunity. Senior members of Krystal’s
commercial team will report directly to Chief Executive Officer
Krish Krishnan on an interim basis as the company initiates a
search for Ms. Chien’s replacement.
“I look forward to working with our commercial leadership team
and expect continued progress of our pre-launch activities without
interruption,” said Krish Krishnan, Chief Executive Officer,
Krystal Biotech. ”Our GEM-3 trial is advancing as planned and we
anticipate completing enrollment early next year. While the
COVID-19 environment has been a challenge to everyone in the
industry, I am pleased that our careful planning has kept patient
enrollment on track across diverse geographical sites in the
US.”
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company
dedicated to developing transformative medicines to treat diseases
caused by protein or gene dysfunction. For more information, please
visit http://www.krystalbio.com.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Krystal Biotech, Inc., including but not
limited to statements about the development of Krystal’s product
candidates, such as plans for the design, conduct and timelines of
ongoing clinical trials of beremagene geperpavec (“B-VEC”), KB105,
KB104, KB301 and KB407; the clinical utility of B-VEC, KB105,
KB104, KB301 and KB407, and Krystal’s plans for filing of
regulatory approvals and efforts to bring B-VEC, KB105, KB104,
KB301 and KB407 to market; the market opportunity for and the
potential market acceptance of B-VEC, KB105, KB104, KB301 and
KB407; plans to pursue research and development of other product
candidates; the sufficiency of Krystal’s existing cash resources;
the unanticipated impact of COVID-19 on Krystal’s business
operations, pre-clinical activities and clinical trials; and other
statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “likely,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation and conduct of clinical
trials, availability and timing of data from clinical trials,
whether results of early clinical trials or trials will be
indicative of the results of ongoing or future trials,
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals, the availability or
commercial potential of product candidates including B-VEC, KB105,
KB104, KB301 and KB407, the sufficiency of cash resources and need
for additional financing and such other important factors as are
set forth under the caption “Risk Factors” in Krystal’s annual and
quarterly reports on file with the U.S. Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent Krystal’s views as of the date of this
release. Krystal anticipates that subsequent events and
developments will cause its views to change. However, while Krystal
may elect to update these forward-looking statements at some point
in the future, it specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing Krystal’s views as of any date subsequent to the date
of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201016005404/en/
Investors: Whitney Ijem wijem@krystalbio.com
Media: Mary Coyle TellMed Strategies
mary.coyle@tmstrat.com
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jul 2023 to Jul 2024